CTIS2023-504132-18-00进行中（未招募）1 期
CFA-1031-2-23
aboratorios Cinfa S.A.0 个研究点目标入组 36 人开始时间: 2023年3月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Bioequivalence of Vortioxetine 20 mg Film-Coated Tablets in Healthy Participants Under Fasting ConditionsCTIS2023-509419-10-00aboratorios Cinfa S.A.24
进行中（未招募）
1 期
Conducting a quality study of the medicinal product - Vortioxetineo therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-509946-36-00CCDRD Cooperative Clinical Drug Research and Development AG36
招募中
1 期
FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.CTIS2023-505266-29-00Xenothera246
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-00Helsinn Healthcare S.A.74